Ainos, Inc. (NASDAQ:AIMD) Short Interest Up 289.3% in May

12 Jun 2026, 18:43 by Mitch Edgeman · The Markets Daily

Ainos, Inc. (NASDAQ:AIMD – Get Free Report) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 91,823 shares, an increase of 289.3% from the May 14th total of 23,588 shares. Based on an average trading volume of 2,248,715 shares, the short-interest ratio is presently 0.0 days. Approximately 1.2% of the shares of the company are short sold.

Ainos Price Performance

Shares of NASDAQ AIMD traded up $0.01 during trading on Friday, hitting $1.93. The company had a trading volume of 17,861 shares, compared to its average volume of 548,193. The company has a market cap of $16.44 million, a P/E ratio of -0.67 and a beta of 2.41. Ainos has a 52 week low of $1.26 and a 52 week high of $4.50. The business’s 50-day moving average is $1.83 and its 200 day moving average is $1.81. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.50 and a current ratio of 0.55.

Ainos (NASDAQ:AIMD – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share (EPS) for the quarter. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.

Analyst Ratings Changes

Separately, Weiss Ratings raised Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 26th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Get Our Latest Stock Report on AIMD

Insider Buying and Selling at Ainos

In other Ainos news, major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of Ainos stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $2.36, for a total value of $96,760.00. Following the completion of the transaction, the insider directly owned 948,925 shares in the company, valued at $2,239,463. The trade was a 4.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Chun-Jung Tsai sold 27,718 shares of Ainos stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $1.87, for a total value of $51,832.66. Following the completion of the transaction, the director owned 658,199 shares of the company’s stock, valued at approximately $1,230,832.13. The trade was a 4.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders purchased 7,800 shares of company stock worth $15,946 and sold 179,788 shares worth $359,247. 9.79% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ainos

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its position in Ainos by 13.1% during the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after purchasing an additional 7,700 shares in the last quarter. Mariner LLC purchased a new position in shares of Ainos during the 4th quarter valued at $37,000. Two Sigma Investments LP purchased a new position in shares of Ainos during the 3rd quarter valued at $80,000. Finally, DRW Securities LLC grew its holdings in shares of Ainos by 272.6% during the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after acquiring an additional 48,439 shares in the last quarter.

About Ainos

(Get Free Report)

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.